Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

GTI-2040 phase I/II trial on target for completion by year-end

May 25, 2000

Proteasome inhibitor MG-132 endowed with antineoplastic activity

May 25, 2000

DDW presentations support efficacy of exisulind in FAP and related conditions

May 24, 2000

Inhibitors of cyclin-dependent kinases claimed by DuPont for cancer

May 24, 2000

Proteasome inhibitors and their use presented by Max Planck

May 24, 2000

Marine sponges yield new biologically active discorhabdin compounds

May 24, 2000

Epimmune and Pharmacia report data on promising cancer vaccine

May 24, 2000

NCI signs CRADA with Exelixis

May 24, 2000

New PYY analogue with picomolar affinity for Y4 receptors presented at DDW

May 23, 2000

SuperGen acquires rights to lucanthone for treatment of brain tumors

May 23, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...